Skip to content

JNJ-53718678

DRUG9 trials

Sponsors

Janssen Sciences Ireland UC, Janssen Research & Development, LLC

Conditions

HealthyHepatic ImpairmentRespiratory Syncytial VirusRespiratory Syncytial Virus InfectionsVirus Diseases

Phase 1

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
TerminatedNCT02593851
Janssen Sciences Ireland UCRespiratory Syncytial Virus Infections, Virus Diseases
Start: 2015-12-04End: 2017-11-10Updated: 2019-12-06
A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults
CompletedNCT02729467
Janssen Research & Development, LLCHealthy
Start: 2016-03-31End: 2016-06-30Updated: 2025-02-03
A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation
CompletedNCT02945007
Janssen Research & Development, LLCHealthy
Start: 2016-11-08End: 2020-01-16Updated: 2020-03-10
A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants
CompletedNCT03002779
Janssen Research & Development, LLCHealthy
Start: 2017-01-26End: 2017-03-20Updated: 2017-05-31
A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants
CompletedNCT04090086
Janssen Research & Development, LLCHealthy
Start: 2019-09-16End: 2019-12-10Updated: 2025-02-03
A Study of JNJ-53718678 in Participants With Hepatic Impairment
TerminatedNCT04332523
Janssen Research & Development, LLCHepatic Impairment
Start: 2020-08-17End: 2022-03-16Updated: 2022-06-13

Phase 2

Unknown Phase

Related Papers